Transcode Therapeutics, Inc. (NASDAQ:RNAZ)
| Market Cap | $1.23M-87.2% |
| Revenue (ttm) | $0 |
| Net Income | -$145.36M-435.7% |
| EPS | -$54.23+85.0% |
| Shares Out | 1.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,671 |
| Open | $1.35 |
| Previous Close | $1.30 |
| Day's Range | $1.01 - $1.35 |
| 52-Week Range | $1.01 - $12.60 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 3, 2027 |
About RNAZ
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Next catalysts
- Mar 3, 2027Earnings report
$RNAZ stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RNAZ holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RNAZ's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RNAZ Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RNAZ patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RNAZ from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RNAZ
| VXFVanguard Extended Market ETF | $10.67K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from RNAZ’s recent data — informational, not investment advice
